Clinical Trials Directory

Trials / Completed

CompletedNCT03670043

Tolerance & Responsiveness Improvement for Metformin (TRIM)

Tolerance & Responsiveness Improvement for Metformin (TRIM): Open-label, Parallel-group Randomized Trial, Phase 4

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
29 (actual)
Sponsor
West Side Institute for Science and Education · Academic / Other
Sex
Male
Age
20 Years – 70 Years
Healthy volunteers
Not accepted

Summary

The overall goal is to explore the hypothesis that prebiotic fiber Psyllium will ameliorate diarrhea in African American men (AAM) with Type2 Diabetes Mellitus (T2D).

Conditions

Interventions

TypeNameDescription
DRUGPsyllium powderTo evaluate whether Psyllium will alleviate diarrhea
DRUGMetformin Extended Release Oral TabletMetformin Extended Release Oral Tablet is standard of care for diarrhea in patients taking metformin

Timeline

Start date
2019-03-19
Primary completion
2020-10-15
Completion
2021-08-15
First posted
2018-09-13
Last updated
2021-09-10

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT03670043. Inclusion in this directory is not an endorsement.

Tolerance & Responsiveness Improvement for Metformin (TRIM) (NCT03670043) · Clinical Trials Directory